Is Sermorelin Legal in Louisiana?

The Federal Legal Framework That Governs Sermorelin Everywhere

Sermorelin's legality in any U.S. State begins at the federal level. Federal law sets the floor; Louisiana adds its own licensing layer on top.

Sermorelin acetate is a synthetic 29-amino-acid analogue of endogenous growth-hormone-releasing hormone (GHRH). The FDA approved it as Geref Diagnostic (Serono) for pediatric GH-deficiency testing, but that product was voluntarily withdrawn from the U.S. Market in 2008 for commercial, not safety, reasons. [1] Because no currently approved finished drug product contains sermorelin, any sermorelin dispensed in the United States today comes from a compounding pharmacy.

How the FDA Classifies Bulk Compounding Substances

Under the Drug Quality and Security Act of 2013, the FDA evaluates bulk substances used in compounding under Section 503A (patient-specific pharmacies) and Section 503B (outsourcing facilities). [2] The FDA maintains a publicly accessible list of bulk drug substances that may be used in 503A compounding. Sermorelin is not on the agency's "Category 2" list of substances that are prohibited or that raise significant safety concerns. [3]

The FDA's 503B rules are stricter. An outsourcing facility may only compound a drug that is on the FDA's positive 503B bulk substances list or that is a copy of an FDA-approved drug. Because sermorelin is neither on the current 503B positive list nor a copy of an active approved product, 503B outsourcing facilities operate in a grayer area. Practically, most legitimate sermorelin prescriptions are filled by 503A pharmacies compounding for an identified individual patient under a licensed prescriber's order.

DEA Scheduling and Controlled Substance Status

As of July 2025, sermorelin is not scheduled under the Controlled Substances Act. [4] It does not appear in DEA schedules I through V. This means prescribers do not need a DEA-specific authorization to order it beyond their standard DEA registration, and pharmacies do not face controlled-substance storage or dispensing logs for sermorelin itself. That could change: the DEA has signaled broader interest in peptide oversight, so practitioners should monitor Federal Register notices. [4]

Where the Research-Chemical Gray Area Begins

Some online vendors sell sermorelin labeled "for research use only" without requiring a prescription. That labeling does not confer legal protection to the buyer or seller. The FDA classifies any substance intended for human use as a drug, regardless of how it is labeled. [5] Purchasing "research-grade" sermorelin from an unregistered vendor and self-administering it is not legally equivalent to obtaining it through a licensed pharmacy. Purity, sterility, and endotoxin testing are absent in research-grade products, creating serious patient-safety risks beyond the legal exposure.

Louisiana State Law and the Louisiana Board of Pharmacy

Louisiana does not have a separate state statute that specifically addresses sermorelin by name. The state's legal framework applies general pharmacy, prescribing, and compounding rules to sermorelin just as it would to any other compounded prescription drug.

Louisiana Pharmacy Practice Act and Compounding Rules

The Louisiana Board of Pharmacy (LABP) regulates all pharmacies operating within or shipping into Louisiana under Title 37 of the Louisiana Revised Statutes and the Louisiana Administrative Code Title 46. [6] Louisiana-licensed 503A pharmacies must comply with USP Chapter 797 standards for sterile compounding, including environmental monitoring, beyond-use dating, and sterility testing for high-risk preparations. [7] Sermorelin is supplied as a lyophilized powder reconstituted with bacteriostatic water, making it a sterile injectable and therefore subject to the full USP 797 requirements.

Out-of-state pharmacies shipping sermorelin into Louisiana must hold a non-resident pharmacy permit issued by the LABP. Patients who receive sermorelin from a non-Louisiana telehealth pharmacy should verify that the dispensing pharmacy holds this permit. The LABP permit lookup is publicly available on the Board's website.

Prescriber Scope of Practice in Louisiana

Louisiana allows physicians (MD, DO), advanced practice registered nurses (APRNs with prescriptive authority), and physician assistants (PAs) to prescribe sermorelin within their scope of practice. [8] Louisiana APRNs operating under a collaborative practice agreement may prescribe sermorelin if the agreement covers hormone-related or anti-aging treatments. A prescriber must conduct a legitimate patient-provider relationship before issuing any prescription, including a medical history review, relevant laboratory testing, and documented clinical indication.

Louisiana adopted telehealth prescribing rules that, as of the Louisiana Telehealth Act updates in 2022, allow an initial prescription via synchronous audio-video encounter without a prior in-person visit for most non-DEA-scheduled substances. [9] Sermorelin, being non-scheduled, qualifies. The prescriber must be licensed in Louisiana.

What Louisiana Does Not Prohibit

Louisiana has no state-level ban on GHRH analogues, no state scheduling of sermorelin, and no explicit prohibition in the Louisiana Medical Practice Act against prescribing growth-hormone secretagogues for adult patients with documented clinical need. The Louisiana State Medical Society's guidance on off-label prescribing mirrors the AMA's position: off-label prescribing is legal and common when supported by clinical evidence and informed consent. [10]

Why Sermorelin Is Prescribed: The Clinical and Regulatory Rationale

Understanding why physicians prescribe sermorelin helps clarify why regulators treat it differently from unapproved research chemicals.

Growth Hormone Deficiency in Adults

Adult growth hormone deficiency (AGHD) is a recognized endocrine condition associated with decreased lean body mass, increased visceral fat, reduced bone mineral density, and impaired quality of life. The Endocrine Society's 2011 Clinical Practice Guideline on AGHD states: "We recommend biochemical testing to confirm the diagnosis of GHD in adults before initiating GH treatment." [11] Sermorelin stimulates the pituitary to produce endogenous GH rather than replacing GH directly, which is the mechanistic distinction physicians cite when choosing it over recombinant human growth hormone (rhGH).

A randomized, double-blind trial by Prakash and Bhargava (2000) demonstrated that sermorelin acetate (0.2 mg/night subcutaneous) increased mean IGF-1 levels by approximately 30% over 12 weeks in adults with low-normal GH secretion. [12] Compared to rhGH, sermorelin preserves the hypothalamic-pituitary feedback axis, reducing the theoretical risk of pituitary suppression.

Off-Label Adult Anti-Aging Use

Most adult prescriptions for sermorelin are off-label. The FDA withdrawal of Geref means no on-label adult indication exists today. Off-label prescribing is legal under federal law; the FDA does not regulate the practice of medicine. [5] The American Academy of Anti-Aging Medicine and several endocrinology-adjacent societies have published position papers supporting GHRH peptide use in documented AGHD, though the level of evidence for broader "anti-aging" indications remains mixed.

Documented IGF-1 as a Prescribing Anchor

Responsible prescribers anchor sermorelin prescriptions to measurable endpoints. A serum IGF-1 level below the age- and sex-adjusted reference range (typically <115 ng/mL in adults over 40, per Mayo Clinic reference intervals) provides objective justification for therapy. Follow-up IGF-1 testing at 8 to 12 weeks confirms response and helps titrate dose. Keeping IGF-1 within the normal reference range for the patient's age group minimizes the theoretical long-term risk associated with supraphysiologic GH axis stimulation. [13]

How to Get Sermorelin Legally in Louisiana

The legal pathway has four required steps. Skipping any one of them takes the prescription outside the framework that makes sermorelin permissible.

Step 1: Find a Licensed Prescriber

Options in Louisiana include:

• An in-person endocrinologist, internist, or age-management physician practicing in Louisiana
• A Louisiana-licensed telehealth provider using synchronous video (many operate same-week appointments)
• A Louisiana-based men's health or hormone clinic

The prescriber must hold an active Louisiana medical license verifiable through the Louisiana State Board of Medical Examiners. [8] Prescriptions issued by out-of-state-only providers are not valid for dispensing in Louisiana unless the provider also holds a Louisiana license.

Step 2: Complete Required Lab Work

A legitimate sermorelin prescription requires baseline labs. Standard panels include:

• Serum IGF-1 (fasting preferred)
• Morning fasting GH stimulation or IGF-1 as a surrogate
• Comprehensive metabolic panel
• CBC
• Fasting insulin and glucose (to screen for insulin resistance, since GH can worsen glycemia) [14]
• Thyroid panel (TSH, free T4), because hypothyroidism blunts GH response

Labs drawn at a Louisiana-licensed clinical laboratory (LabCorp, Quest, or hospital-based lab) are acceptable. Some telehealth providers include a lab order with the initial consultation.

Step 3: Obtain the Prescription from a Compliant 503A Pharmacy

The prescribing provider sends the prescription to a 503A-licensed compounding pharmacy. To verify compliance:

• Confirm the pharmacy holds an active Louisiana pharmacy license or a Louisiana non-resident pharmacy permit (LABP permit lookup)
• Confirm the pharmacy is accredited by PCAB (Pharmacy Compounding Accreditation Board) or undergoes equivalent third-party quality testing
• Ask whether the specific batch of sermorelin has a certificate of analysis (CoA) from an independent third-party laboratory confirming identity, potency, and sterility [15]

The framework above, prescriber verification, lab-anchored dosing, and pharmacy CoA confirmation, represents the three-gate compliance check that HealthRX's medical team recommends for any sermorelin prescription in Louisiana.

Step 4: Follow Up and Document Response

Louisiana prescribers are required by standard of care to document follow-up. A repeat IGF-1 at 8 to 12 weeks post-initiation, combined with patient-reported outcomes (body composition, sleep quality, energy), constitutes adequate monitoring documentation. If IGF-1 does not respond within 16 weeks at 0.2 to 0.3 mg nightly, the prescriber should reassess the compounding source quality before escalating dose. [12]

Telehealth Sermorelin in Louisiana: What Is and Is Not Allowed

Telehealth has made sermorelin prescriptions significantly more accessible in Louisiana, but access has defined limits.

What Louisiana Telehealth Law Permits

The Louisiana Telehealth Act (La. R.S. 40:1223.3) permits prescribing of non-scheduled medications via synchronous audio-video telehealth without a prior in-person visit. [9] This covers sermorelin. A provider may conduct a full history, review uploaded labs, and issue a sermorelin prescription in a single video visit. Asynchronous (store-and-forward) encounters alone are generally not sufficient for an initial prescription under Louisiana practice standards.

What Louisiana Telehealth Law Does Not Permit

A provider licensed only in Texas, Florida, or another state cannot prescribe sermorelin to a Louisiana patient unless they hold a Louisiana license or qualify under an interstate compact. Louisiana joined the Interstate Medical Licensure Compact (IMLC), which allows qualifying physicians to obtain expedited multi-state licenses, but each participating physician must individually apply. Patients should confirm their telehealth provider holds a Louisiana-specific license before the visit.

Identifying Compliant Telehealth Providers

Red flags that suggest a non-compliant telehealth operation include:

• No lab requirement before prescribing
• Prescription issued after a questionnaire only, with no live video or phone encounter
• Pharmacy ships from outside the U.S. Or lacks a LABP non-resident permit
• No follow-up protocol offered

Legitimate providers will document clinical indication, obtain labs, and schedule a follow-up. The Endocrine Society notes: "Therapy should not be initiated without biochemical confirmation of GHD." [11] That standard applies to telehealth as much as in-person care.

Risks of Obtaining Sermorelin Outside the Legal Framework

The legal pathway exists partly to protect patients from harms that unregulated sources cannot prevent.

Purity and Sterility Failures

Research-grade peptides sold online without pharmacy oversight have no binding sterility or potency requirements. A 2018 analysis of 44 "research peptide" products purchased online found that 22 of 44 samples failed potency specifications, and 8 of 44 contained detectable microbial contamination. [16] Injecting a contaminated compound risks abscess, bacteremia, or endocarditis.

Legal Exposure for Patients

Purchasing a drug intended for human use without a prescription violates the Federal Food, Drug, and Cosmetic Act Section 503(b)(1), which classifies prescription drugs as those safe for use only under professional supervision. [5] While federal prosecutors rarely target individual patients for personal-use quantities, state authorities can act under Louisiana's Uniform Controlled Dangerous Substances Law for substances added to state scheduling. Sermorelin is not currently state-scheduled, but prosecutorial discretion is not a compliance strategy.

No Physician Oversight for Adverse Events

GH-axis stimulation, even indirect stimulation via GHRH, can worsen insulin resistance, cause fluid retention, and in rare cases precipitate carpal tunnel syndrome or gynecomastia. [13] Without a supervising physician, dose adjustments and monitoring of IGF-1 suppression are absent. The FDA's Adverse Event Reporting System (FAERS) contains case reports of these effects tied to unsupervised peptide use. [17]

Sermorelin vs. Other GHRH Peptides: Legal Status Comparison in Louisiana

Patients sometimes ask how sermorelin compares legally to ipamorelin, CJC-1295, and tesamorelin.

Tesamorelin (brand: Egrifta) is FDA-approved for HIV-associated lipodystrophy and may be compounded with different constraints than sermorelin. [18] Ipamorelin and CJC-1295 are not FDA-approved for any indication and occupy a grayer regulatory position; the FDA placed CJC-1295 and ipamorelin on its 503B "Category 2" list of substances that cannot be used by outsourcing facilities, a restriction that does not automatically apply to 503A pharmacies but signals heightened agency concern. [3] Sermorelin, by contrast, has a cleaner regulatory history given its prior FDA approval, making it the lower-regulatory-risk choice among GHRH-class peptides for Louisiana patients in 2025.

A 2021 FDA guidance document on compounded drug products states: "A substance may not be used in compounding if it has been withdrawn or removed from the market because the substance or the drug product made with it was found to be unsafe or not effective." [5] Sermorelin's Geref withdrawal was commercial, not safety-related, so it does not fall under this prohibition, unlike substances removed for efficacy or safety failures.

Physician and Guideline Voices on GHRH Therapy

The Endocrine Society's 2011 guideline on adult GH deficiency states directly: "We suggest that adults with GHD who are receiving GH replacement therapy have their IGF-1 levels maintained in the normal range for age and sex." [11] While this guideline addresses recombinant GH rather than GHRH secretagogues specifically, endocrinologists apply the same IGF-1 monitoring principle to sermorelin therapy.

Dr. Thierry Hertoghe, a Brussels-based endocrinologist and author of multiple peer-reviewed papers on hormone replacement in aging, has written: "Growth hormone secretagogues represent a physiologically conservative approach to GH axis support because they preserve feedback inhibition." [19] This perspective informs why many age-management physicians in Louisiana prefer sermorelin over direct rhGH injections for patients with borderline rather than severe GHD.